Recent Scientific Articles

JULY 2015 - Current Publications

Alayev, Anya, Sara Malka Berger, and Marina K. Holz. 2015. “Resveratrol as a Novel Treatment for Diseases with mTOR Pathway Hyperactivation.” Annals of the New York Academy of Sciences, July. doi:10.1111/nyas.12829.

Bai, Yadan, Baoqin Xuan, Haiyan Liu, Jin Zhong, Dong Yu, and Zhikang Qian. 2015. “Tuberous Sclerosis Complex Protein 2-Independent Activation of mTORC1 by Human Cytomegalovirus pUL38.” Journal of Virology 89 (15): 7625–35. doi:10.1128/JVI.01027-15.

Bissler, John J., John Christopher Kingswood, Elzbieta Radzikowska, Bernard A. Zonnenberg, Michael Frost, Elena Belousova, Matthias Sauter, et al. 2015. “Everolimus for Renal Angiomyolipoma in Patients with Tuberous Sclerosis Complex or Sporadic Lymphangioleiomyomatosis: Extension of a Randomized Controlled Trial.” Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association, July. doi:10.1093/ndt/gfv249.

Dibble, Christian C., and Lewis C. Cantley. 2015. “Regulation of mTORC1 by PI3K Signaling.” Trends in Cell Biology, July. doi:10.1016/j.tcb.2015.06.002.

Fang, Chunmin, Juan Yu, Yuechen Luo, Song Chen, Weiqiang Wang, Chunxiao Zhao, Zhina Sun, et al. 2015. “Tsc1 Is a Critical Regulator of Macrophage Survival and Function.” Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology 36 (4). doi:10.1159/000430306.

Huelsmann, Lorel, D. Nathan W. Kim, Raquibul Hannan, Lori M. Watumull, and James Brugarolas. 2015. “Selective Efficacy of Temsirolimus on Bone Metastases in Chromophobe Renal Cell Carcinoma.” Clinical Genitourinary Cancer 13 (4): e321–23. doi:10.1016/j.clgc.2014.12.007.

Rabban, Joseph T., Brandie Firetag, Ankur R. Sangoi, Miriam D. Post, and Charles J. Zaloudek. 2015. “Incidental Pelvic and Para-Aortic Lymph Node Lymphangioleiomyomatosis Detected During Surgical Staging of Pelvic Cancer in Women Without Symptomatic Pulmonary Lymphangioleiomyomatosis or Tuberous Sclerosis Complex.” The American Journal of Surgical Pathology 39 (8): 1015–25. doi:10.1097/PAS.0000000000000416.

Rabenou, Rahmin A., and Hearns W. Charles. 2015. “Differentiation of Sporadic Versus Tuberous Sclerosis Complex-Associated Angiomyolipoma.” AJR. American Journal of Roentgenology 205 (2). doi:10.2214/AJR.14.14255.

Radzikowska, Elzbieta. 2015. “Lymphangioleiomyomatosis: New Treatment Perspectives.” Lung 193 (4): 467–75. doi:10.1007/s00408-015-9742-6.

Ray, Ramesh M., Mitul Bavaria, and Leonard R. Johnson. 2015. “Interaction of Polyamines and mTOR Signaling in the Synthesis of Antizyme (AZ).” Cellular Signalling 27 (9): 1850–59. doi:10.1016/j.cellsig.2015.06.002.

Rensing, Nicholas, Lirong Han, and Michael Wong. 2015. “Intermittent Dosing of Rapamycin Maintains Antiepileptogenic Effects in a Mouse Model of Tuberous Sclerosis Complex.” Epilepsia 56 (7): 1088–97. doi:10.1111/epi.13031.

Tran, Lily H., and Mary L. Zupanc. 2015. “Long-Term Everolimus Treatment in Individuals with Tuberous Sclerosis Complex: A Review of the Current Literature.” Pediatric Neurology 53 (1). doi:10.1016/j.pediatrneurol.2014.10.024.

Xu, Geyang, Ziru Li, Li Ding, Hong Tang, Song Guo, Hongbin Liang, Huadong Wang, and Weizhen Zhang. 2015. “Intestinal mTOR Regulates GLP-1 Production in Mouse L Cells.” Diabetologia 58 (8): 1887–97. doi:10.1007/s00125-015-3632-6.

Zhang, Dan, Bo Tang, Xia Xie, Yu-Feng Xiao, Shi-Ming Yang, and Jian-Wei Zhang. 2015. “The Interplay between DNA Repair and Autophagy in Cancer Therapy.” Cancer Biology & Therapy 16 (7): 1005–13. doi:10.1080/15384047.2015.1046022.

Zhang, Yinan, and Brendan D. Manning. 2015. “mTORC1 Signaling Activates NRF1 to Increase Cellular Proteasome Levels.” Cell Cycle (Georgetown, Tex.) 14 (13): 2011–17. doi:10.1080/15384101.2015.1044188.



JUNE 2015 - Current Publications

Atochina-Vasserman, Elena N., Chang-Jiang Guo, Elena Abramova, Thea N. Golden, Michael Sims, Melane L. James, Michael F. Beers, Andrew J. Gow, and Vera P. Krymskaya. 2015. “Surfactant Dysfunction and Lung Inflammation in the Female Mouse Model of Lymphangioleiomyomatosis.” American Journal of Respiratory Cell and Molecular Biology 53 (1). doi:10.1165/rcmb.2014-0224OC.

Bee, Janet, Rupesh Bhatt, Ian McCafferty, and Simon R. Johnson. 2015. “A 4-Year Prospective Evaluation of Protocols to Improve Clinical Outcomes for Patients with Lymphangioleiomyomatosis in a National Clinical Centre.” Thorax, June. doi:10.1136/thoraxjnl-2015-207171.

Ellender, Claire M., Trevor J. Williams, Julian Gooi, Gregory I. Snell, and Helen M. Whitford. 2015. “Management of Refractory Chylothorax in Pulmonary Lymphangioleiomyomatosis.” Respirology Case Reports 3 (2): 72–74. doi:10.1002/rcr2.105.

Goldberg, Hilary J., Sergio Harari, Vincent Cottin, Ivan O. Rosas, Elizabeth Peters, Shibadas Biswal, Yi Cheng, et al. 2015. “Everolimus for the Treatment of Lymphangioleiomyomatosis: A Phase II Study.” The European Respiratory Journal, June. doi:10.1183/09031936.00210714.

Grzegorek, Irmina, Dido Lenze, Mariusz Chabowski, Dariusz Janczak, Malgorzata Szolkowska, Renata Langfort, Andrzej Szuba, and Piotr Dziegiel. 2015. “Immunohistochemical Evaluation of Pulmonary Lymphangioleiomyomatosis.” Anticancer Research 35 (6): 3353–60.

Grzegorek, Irmina, Ewa Zuba-Surma, Mariusz Chabowski, Dariusz Janczak, Andrzej Szuba, and Piotr Dziegiel. 2015. “Characterization of Cells Cultured from Chylous Effusion from a Patient with Sporadic Lymphangioleiomyomatosis.” Anticancer Research 35 (6): 3341–51.

Gupta, Nishant, Robert Vassallo, Kathryn A. Wikenheiser-Brokamp, and Francis X. McCormack. 2015a. “Diffuse Cystic Lung Disease. Part I.” American Journal of Respiratory and Critical Care Medicine 191 (12): 1354–66. doi:10.1164/rccm.201411-2094CI.
———. 2015b. “Diffuse Cystic Lung Disease. Part II.” American Journal of Respiratory and Critical Care Medicine 192 (1). doi:10.1164/rccm.201411-2096CI.

Priolo, Carmen, Stephane J. H. Ricoult, Damir Khabibullin, Harilaos Filippakis, Jane Yu, Brendan D. Manning, Clary Clish, and Elizabeth P. Henske. 2015. “Tuberous Sclerosis Complex 2 Loss Increases Lysophosphatidylcholine Synthesis in  Lymphangioleiomyomatosis.” American Journal of Respiratory Cell and Molecular Biology 53 (1). doi:10.1165/rcmb.2014-0379RC.

Richards, J. Caleb, David A. Lynch, and Jonathan H. Chung. 2015. “Cystic and Nodular Lung Disease.” Clinics in Chest Medicine 36 (2). doi:10.1016/j.ccm.2015.02.011.

Spalgais, S., D. Gothi, and A. K. Verma. 2015. “Pulmonary Choriostoma in a Case of Tuberous Sclerosis Complex.” Journal of Postgraduate Medicine 61 (3): 193–96. doi:10.4103/0022-3859.159426.

Taveira-DaSilva, Angelo M., Amanda M. Jones, Patricia Julien-Williams, Thomas Shawker, Connie G. Glasgow, Mario Stylianou, and Joel Moss. 2015. “Effect of Fasting on the Size of Lymphangioleiomyomas in Patients with Lymphangioleiomyomatosis.” Chest, June. doi:10.1378/chest.15-0456.

Von Ranke, Felipe Mussi, Glaucia Zanetti, Jorge Luiz Pereira E Silva, Cesar Augusto Araujo Neto, Myrna C. B. Godoy, Carolina A. Souza, Alexandre Dias Mancano, et al. 2015. “Tuberous Sclerosis Complex: State-of-the-Art Review with a Focus on Pulmonary Involvement.” Lung, June. doi:10.1007/s00408-015-9750-6.

Wu, Kai, and Hui-Yu Lu. 2015. “Sporadic Lymphangioleiomyomatosis with Bloody Sputum as an Initial Symptom: A Case Report and Review of the Literature.” Experimental and Therapeutic Medicine 9 (6). doi:10.3892/etm.2015.2397.



MAY 2015 - Current Publications


Cai, Xiong, Gustavo Pacheco-Rodriguez, Mary Haughey, Leigh Samsel, Suowen Xu, Hai-Ping Wu, J. Philip McCoy, Mario Stylianou, Thomas N. Darling, and Joel Moss. 2014a. “Sirolimus Decreases Circulating Lymphangioleiomyomatosis Cells in Patients with Lymphangioleiomyomatosis.” Chest 145 (1): 108–12. doi:10.1378/chest.13-1071.

El-Chemaly, Souheil, and Elizabeth P. Henske. 2015. “The next Breakthrough in LAM Clinical Trials May Be Their Design: Challenges in Design and Execution of Future LAM Clinical Trials.” Expert Review of Respiratory Medicine 9 (2).  doi:10.1586/17476348.2015.1024663.

El-Chemaly, Souheil, Hilary J. Goldberg, and Allan R. Glanville. 2014. “Should Mammalian Target of Rapamycin Inhibitors Be Stopped in Women with Lymphangioleiomyomatosis Awaiting Lung Transplantation?” Expert Review of Respiratory Medicine 8 (6): 657–60. doi:10.1586/17476348.2014.956728.

Fan, Daming, Li Ding, Hui Liu, Jigang Wang, Wenwen Ran, Yujun Li, and Dongliang Lin. 2014. “Effusion Cytology: An Effective Method for the Diagnosis of Pulmonary Lymphangioleiomyomatosis.” Journal of Thoracic Disease 6 (5): E54–57. doi:10.3978/j.issn.2072-1439.2014.03.12.

Gao, Ling, Michael M. Yue, Jennifer Davis, Elisabeth Hyjek, and Lucia Schuger. 2014. “In Pulmonary Lymphangioleiomyomatosis Expression of Progesterone Receptor Is Frequently Higher than that of Estrogen Receptor.” Virchows Archiv : An International Journal of Pathology 464 (4). doi:10.1007/s00428-014-1559-9.

Gupta, R., M. Kitaichi, Y. Inoue, R. Kotloff, and F. X. McCormack. 2014a&b. “Lymphatic Manifestations of Lymphangioleiomyomatosis.” Lymphology 47 (3): 106–17.

Li, Jing, Alfredo Csibi, Sun Yang, Gregory R. Hoffman, Chenggang Li, Erik Zhang, Jane J. Yu, and John Blenis. 2015. “Synthetic Lethality of Combined Glutaminase and Hsp90 Inhibition in mTORC1-Driven Tumor Cells.” Proceedings of the National Academy of Sciences of the United States of America 112 (1): E21–29. doi:10.1073/pnas.1417015112.

McCormack, Francis X., William D. Travis, Thomas V. Colby, Elizabeth P. Henske, and Joel Moss. 2012. “Lymphangioleiomyomatosis: Calling It What It Is: A Low-Grade, Destructive, Metastasizing Neoplasm.” American Journal of Respiratory and Critical Care Medicine 186 (12): 1210–12. doi:10.1164/rccm.201205-0848OE.

Henske, Elizabeth P., and Francis X. McCormack. 2012. “Lymphangioleiomyomatosis - a Wolf in Sheep’s Clothing.” The Journal of Clinical Investigation 122 (11): 3807–16. doi:10.1172/JCI58709.

Priolo, Carmen, Stephane J. H. Ricoult, Damir Khabibullin, Harilaos Filippakis, Jane Yu, Brendan D. Manning, Clary Clish, and Elizabeth P. Henske. 2015. “TSC2 Loss Increases Lysophosphatidylcholine Synthesis in Lymphangioleiomyomatosis.” American Journal of Respiratory Cell and Molecular Biology, March. doi:10.1165/rcmb.2014-0379RC.

Yao, Jianhua, Angelo M. Taveira-DaSilva, Amanda M. Jones, Patricia Julien-Williams, Mario Stylianou, and Joel Moss. 2014. “Sustained Effects of Sirolimus on Lung Function and Cystic Lung Lesions in Lymphangioleiomyomatosis.” American Journal of Respiratory and Critical Care Medicine 190 (11): 1273–82. doi:10.1164/rccm.201405-0918OC.

Yeoh, Zhao W., Vidya Navaratnam, Rupesh Bhatt, Ian McCafferty, Richard B. Hubbard, and Simon R. Johnson. 2014a. “Natural History of Angiomyolipoma in Lymphangioleiomyomatosis: Implications for Screening and Surveillance.” Orphanet Journal of Rare Diseases 9. doi:10.1186/s13023-014-0151-3.

Young, Lisa, Hye-Seung Lee, Yoshikazu Inoue, Joel Moss, Lianne G. Singer, Charlie Strange, Koh Nakata, et al. 2013. “Serum VEGF-D a Concentration as a Biomarker of Lymphangioleiomyomatosis Severity and Treatment Response: A Prospective Analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) Trial.” The Lancet. Respiratory Medicine 1 (6): 445–52. doi:10.1016/S2213-2600(13)70090-0.



Continuing Education Opportunities

The European Respiratory Society (ERS) is offering several courses as continuing medical education. Please visit the ERS website at click here for a list of courses and a description of each.